Global Markets for Drug Repurposing

Report Highlights

The global market for drug repurposing will grow from nearly $24.4 billion in 2015 to nearly $31.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.1% for the period of 2015-2020.

Report Includes

• An overview of the global markets for drug re-purposing, (also known as re-positioning or re-profiling) referring to studies about a compound or a biologic agent that treats one condition and sees if that particular compound is safe and effective for treating other diseases.
• Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
• A look at how human intervention and investigation early in the drug discovery process is helping in faster development of therapeutics.
• Evaluation of drug-repurposing compared to traditional drug development where cost and the time for the drug to be available in the market is greatly reduced since the re-purposed drug has already passed a significant number of tests.
• Coverage of how the discovery process for repurposing drugs has accelerated in recent years due to the emergence of new tools and technologies.
• Profiles of major players in the industry.

SCOPE OF THE REPORT

This report provides a global overview of drug repurposing, also known as repositioning or reprofiling, including the techniques and applications in various therapies. The report deals with the global market for repurposed drugs in three main areas: market by application of repurposed drugs, by usage of repurposed drugs and by application site (i.e., whether they are used orally or intravenously). The application area is divided into types of disorders (i.e., repurposed drugs in central nervous disorders, cardiovascular disorders, oncology, metabolic, autoimmune and other disorders). Market by usage is analyzed on the basis that repurposed drugs are used alone in single therapy or used in combination with other drugs.

Excluded from this report are drugs that are not yet approved as repurposed drugs. BCC Research analyzes the market and its applications, regulatory environment, technologies involved, market projections and market shares. The market is mainly divided into theU.S.and the rest of the world (ROW).

Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the drug repurposing market. The key players are Novartis AG, Abbott Healthcare, Pfizer Inc., Johnson & Johnson and Hoffmann-La Roche. Other significant players are the generic drug manufacturers such as Sandoz, Mylan Inc., and Teva Pharmaceuticals. The chapter on company profiles also includes even core drug repurposing companies such as SOM Biotech, Biovista Inc. and Sosei Group Ltd.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.